Evolus is a medical aesthetics company focused on providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures.Evolus’ primary market is self-pay healthcare. Our lead product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.Evolus, Inc., incorporated on November 9, 2012, is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.
|Bank Name||Evolus, Inc.|
|CEO||Dr. Rui Avelar M.D.|